WHIPPANY, NJ —Lori Moore, most recently a Deloitte managing director, has joined Bayer as the company’s head of pharmaceutical communications in the US.

Moore, who started Monday, is responsible for developing and executing external and internal communication strategies for the company’s US pharmaceutical portfolio, with an emphasis on cardiology, oncology, women’s health, hematology and radiology. She reports to senior VP of corporate affairs Raymond Kerins, Jr. and serves on the US corporate affairs and pharmaceutical seadership teams.

Moore replaces Steven Immergut, who departed Bayer last year to join Global Blood Therapeutics as head of corporate communications and investor relations.

Moore spent the last six years in senior communications roles at Deloitte, where she most recently was responsible for creating and implementing a new internal communications strategy. Earlier, she served as the head of communications for Deloitte’s audit and risk advisory business.

Earlier in her career, Moore served as Novo Nordisk’s executive director for communications and public affairs, where she oversaw all strategic communications, including brand and reputation management, crisis management and employee engagement in the US. Experience also includes managing global product communications for Sanofi.